Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.53 |
| ▸ | CTSK | P43235 | 9/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891125 | 0.83 | CTSK (0.50) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL4891122 | 0.83 | CTSK (0.50) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL3640282 | 0.83 | CTSK (0.52) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL3640281 | 0.83 | CTSK (0.52) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL6335150 | 0.82 | CTSK (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29701907 | 0.82 | CTSK (0.51) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL29702002 | 0.82 | CTSK (0.51) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL8461987 | 0.82 | MEN1 (0.60) | CTSSCTSK | |
| SCHEMBL1883313 | 0.81 | CTSK (0.50) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL2187825 | 0.81 | CTSK (0.52) | CTSSCTSKCTSLCTSBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1294700-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | CTSS 1007/4885CTSK 568/4885CTSL 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.